Skyline throws in towel on fundraising; Biosimilar version of Humira under way;

 @FierceBiotech: High blood pressure medicine boosts memories of Alzheimer's-stricken mice. Article | Follow @FierceBiotech

 @RyanMFierce: Novo is confident in heart safety of degludec, Reuters reports. Gotta make the case to Nov. 8 FDA panel, though. More | Follow @RyanMFierce

> A pair of companies is joining forces on a biosimilar version of Abbott's ($ABT) megablockbuster Humira. Item

> Feeling the squeeze of a contracting venture capital industry, Skyline Ventures is shrinking its partnership and postponing its fundraising efforts, Luke Timmerman reports. Article

> The Battle Against Cancer Investment Trust (BACIT) has raised 207 million pounds in an initial public offering, with plans to nix management fees and invest as much as 1% of its capital into cancer drug development and research. Report

> Novartis ($NVS) owes partner Vectura a $5 million milestone payment, triggered by the Swiss pharma giant's EMA filing of its drug QVA149 for smoker's cough or COPD that uses Vectura's inhaler technology. Report

Medical Device News

 @FierceMedDev: Varian Medical Systems booked a banner Q4. Response: investors drove the stock price up more than 16%. Release | Follow @FierceMedDev

 @MarkHFierce: Philips and Elekta are beefing up a joint program focused on blending a linear accelerator with MRI. Release | Follow @MarkHFierce

 @DamianFierce: Bayer has called off the sale of its glucose meter business, according to a German newspaper. Report | Follow @DamianFierce

> Philips, Elekta consortium building MRI/radiation treatment system. News

> St. Jude dealt a blow with heart-plug study. Report

Pharma News

@FiercePharma: Boehringer Ingelheim settles marketing case for just $95M. Story | Follow @FiercePharma

> Germany, France join crowd withdrawing Novartis vaccines. News

> Merck's hustle helps offset Singulair's declines. Report

> Novo's new insulin Tresiba to face tough questions from FDA panel. More

And Finally… Scientists have advanced a method of adding healthy genes in human eggs to address risks of inherited disease. Report

Suggested Articles

Joe Jimenez has (another) new gig. The ex-Novartis boss joined the board of Century Therapeutics, a startup working on off-the-shelf cell therapies.

As Pfizer posts its full-year financials today, as usual it’s also sneaked in several dropped projects from its pipeline.

The short seller thinks Principia’s approach to the treatment of autoimmune diseases is “misguided” and likely to lead to clinical failures.